Background/Objective: The criterion standard for anti-topoisomerase I antibody (anti-topo I antibody) testing in systemic sclerosis (SSc) uses immunodiffusion (ID) techniques, but enzyme-linked immunosorbent assay (ELISA) and multiple-bead technology are often used in current settings to save time and cost. Our aim was to assess the performance of the multiple-bead assay, ELISA, and ID testing methods.
S ystemic sclerosis (SSc) is a rare autoimmune disease that affects the connective tissue of the skin and internal organs. Systemic sclerosis can be heterogeneous, ranging from minimal to severe skin involvement, and may affect the internal organs. Systemic sclerosis has a higher morbidity and mortality than any other rheumatic disease and affects an estimated 240 people per million in the United States. 1, 2 Classification of SSc is based on the 2013 European League Against Rheumatism/American College of Rheumatology classification criteria. 3 These criteria include signs, symptoms, and assessment of 3 SSc-related autoantibodies: anticentromere, anti-topoisomerase I (anti-topo I, also known as anti-Scl-70), and anti-RNA polymerase III. In the United States, anti-topo I antibody has been found in approximately 20% of patients with SSc. 4, 5 The presence of anti-topo I antibody is associated with an increased risk of developing diffuse cutaneous SSc (dcSSc), scleroderma renal crisis, and scleroderma-related progressive interstitial lung disease (ILD). 4, 6 In the United States, approximately 30% to 40% of dcSSc patients are positive for the anti-topo I antibody compared with approximately 10% to 20% of limited cutaneous SSc (lcSSc) patients. [7] [8] [9] Sensitivity and specificity of the anti-topo I antibody test for a diagnosis of SSc have been reported at 20% to 40% and 90% to 100%, respectively, [10] [11] [12] whereas sensitivity and specificity of anti-topo I antibody for the dcSSc subgroup have been reported at 40% to 60% and 95%, respectively. 11, 13 Current laboratory testing for the anti-topo I antibody varies by institution and includes multiplex magnetic bead technology (multiple-bead assay), enzyme-linked immunosorbent assay (ELISA), and immunodiffusion (ID). The criterion standard for anti-topo I antibody testing uses ID techniques; however, multiple-bead testing is the most prevalent in clinical settings as they are automated and therefore are less time consuming. The multiple-bead testing method allows multiple analytes to be measured in a single run of the assay, which results in the advantages of increased efficiency and reduced expense. 14 However, there has been concern that using this methodology causes increased false positivity of the anti-topo I antibody.
Our aim was to assess the performance of the multiple-bead assay, ELISA, and ID testing methods for anti-topo I antibody within a single academic center.
METHODS
We conducted a study of 129 patients at the University of Michigan whose extractable nuclear antigen 10 (ENA-10) autoantibody panel tested positive for anti-topo I antibody by multiple-bead technology during a 1-year period from August 2016 to August 2017. Ethics board approval from the University of Michigan Internal Review Board (IRBMED) (HUM00142710) with a waiver of informed consent for secondary use of existing identifiable data was obtained. Anti-topo I antibody testing at the University of Michigan Clinical Immunology Laboratory is performed using the BioPlex 2200 system. This system uses heterogeneous sets of 8-μm-diameter magnetic beads infused with varying ratios of 2 fluorescent classification dyes, creating a series of unique bead sets. Beads within each set are coated with a single purified ligand specific to the particular assay, allowing the capture and detection of corresponding specific analytes from a clinical sample. Target analytes captured on bead surfaces are in turn probed with a corresponding fluorescent conjugate. With excitation and emission spectra distinct from those of the classification dyes used to identify analyte and control beads, the conjugate serves as the "reporter" fluorescence signal.
In this study, all samples positive for the anti-topo I antibody by multiple beads were sent to the RDL Reference Laboratory to be reflexed for ELISA, and all anti-topo I antibodies positive by ELISA were further tested by ID. Anti-topo I antibody ELISA testing was performed on the QUANTA Lite Scl-70 ELISA assay (Inova Diagnostics, San Diego, CA). Anti-topo I antibody testing by ID was performed by a proprietary procedure using an antitopo I antigen from Inova Diagnostics.
In an additional 24 patients who were positive for anti-topo I on the multiple-bead platform, we reviewed the values in international units (IU) and assessed if the values were 1 to 8 IU or more than 8 IU (above the measurement value) and its relationship with the diagnosis of SSc and other connective tissue diseases (CTDs).
Clinical data for all patients were reviewed by the first author and a rheumatologist (D.K.). We assessed if the patients were seen in a rheumatology clinic, if they fulfilled the 2013 American College of Rheumatology/European League Against Rheumatism classification criteria for SSc, and if a diagnosis of SSc was established. If not, we also reviewed if a diagnosis of another CTD was made. For those who were not referred to rheumatology clinic, the charts were reviewed for signs, symptoms, and other autoantibodies suggestive of a CTD. We also documented evidence of internal organ involvement (ILD, gastroesophageal reflux disease, scleroderma renal crisis, or pulmonary hypertension). Systemic sclerosis disease duration was determined using the onset date of the patient's initial non-Raynaud phenomenon sign or symptom. Data were analyzed for predictive values and likelihood ratios (LRs) using frequency tables.
RESULTS
During the period of 1 year, approximately 9500 ENA panels were ordered by physicians at the University of Michigan. Extractable nuclear antigen panels were generally ordered by nonrheumatologists or rheumatologists who considered an underlying CTD. Among these, 129 patients (1.4%) had positive anti-topo I antibody by multiple-bead assay, and of these 129 patients, 51 (39.5%) were positive by ELISA. Of those patients positive by ELISA, 21 (41.2%) were positive by ID (Table 1) .
On chart review of the patients who were positive by multiplebead assay, 34 (26.4%) had SSc, and 9 (26.5%) of these 34 had dcSSc. Twenty-three (17.8%) had other CTDs, with 72 (55.8%) presenting with no evidence of CTD (Table 1 ). Of the 72 presenting with no evidence of CTD, 41 were evaluated by a rheumatologist.
Of the 51 patients who were positive by multiple-bead assay and ELISA, 24 (47.1%) had a diagnosis of SSc, and 8 of these 24 (33.3%) had dcSSc. Seven (13.7%) were diagnosed with other CTDs ( Table 2) . For the 21 patients who were positive by multiplebead assay, ELISA, and ID, 20 (95.2%) were diagnosed with SSc, and 8 of these 20 (40.0%) had dcSSc. Of the 20 patients with SSc, 15 (75.0%) had evidence of internal organ involvement, with the majority of the organ involvement including gastroesophageal reflux disease and/or ILD (Table 3) . Enzyme-linked immunosorbent assay units for those positive by ID ranged from 32 to 231 units. Fourteen (93.3%) of those with values equal to or greater than 110 units were diagnosed with SSc. Enzyme-linked immunosorbent assay units for those positive by ID with a diagnosis of dcSSc ranged from 70 to 129 units, and 6 of these 8 patients had values of more than 110 units.
The positive predictive values for the diagnosis of SSc were 47.1% by multiple-bead assay and ELISA and 95.2% by multiplebead assay, ELISA, and ID, and the positive predictive values for diagnosis of dcSSc were 15.7% by multiple-bead assay and ELISA and 38.1% by multiple-bead assay, ELISA, and ID. The positive LRs for the diagnosis of SSc were 2.5 (negative LR = 0.4) and 2.5 (negative LR = 0.2) for the diagnosis of dcSSc by multiple-bead assay and ELISA. The positive LRs for the diagnosis of SSc were 11.7 (negative LR 0.2) and 3.3 (negative LR = 0.0) for dcSSc by multiple-bead assay, ELISA, and ID.
In an additional 24 patients who were positive for the antitopo I antibody by multiple-bead assay between May 2018 and 
DISCUSSION
Anti-topo I antibody testing is widely used to assist in the diagnosis of SSc and to identify individuals at risk of progressive disease with internal organ involvement. Traditionally, anti-topo I antibody has been utilized because of its perceived high specificity in diagnosing SSc. 10, 11 The criterion standard to evaluate antitopo I antibodies is the ID method, but ID is difficult to automate and requires 2 to 3 days to process. 12 Multiple-bead assay was introduced to save time and material and labor costs and to increase the efficiency of autoantibody testing. 14 This methodology has been largely utilized in the US health care system, but our results suggest a high rate of false-positive rates for anti-topo I by multiple-bead assay, leading to additional testing, inappropriate referral to rheumatologists, and consternation among patients. We believe that our stepwise approach is cost-effective and may help to streamline the diagnosis and care of patients with true-positive anti-topo I antibodies, having been verified by either ELISA or ID.
Immunodiffusion has been traditionally used because of its high specificity for the diagnosis of SSc. 10 When determined by ID, anti-topo I antibodies are rarely seen in healthy controls, nonaffected relatives of patients with SSc, or in patients with other CTDs or primary Raynaud phenomenon. 12 Literature on non-ID techniques show a lower clinical specificity, especially in rheumatic disease controls. 10 Differences in epitope recognition, manner of antigen/epitope display on bead surface, and/or antibody avidity and affinity in solid-phase and liquid-phase assays may explain this discrepancy. 15 Others suggest that the false-positive results may be due to contamination of antigens or binding of anti-DNA/ DNA complexes to topo I. 5 Mahler et al. 5 reviewed the literature for association of antitopo I antibody in those who were diagnosed with systemic lupus erythematosus (SLE). The presence of anti-topo I antibody by ELISA, multiple-bead assay, and other methodologies ranged from 0.0% to 7.7%. 5, 13, [16] [17] [18] [19] [20] [21] [22] [23] Using BioPlex 2200 assay, it ranged from 1.2% to 5.2%. 5, 16, 17 The prevalence was higher in SLE compared with healthy controls in their review. In our cohort, 3.9% had SLE who were positive on multiple-bead assay ( Table 1) .
Screening for the anti-topo I antibody by BioPlex2200 (multiple-bead assay) and ELISA is set to minimize false-negative results, although it has been found that patients with SSc tend to have higher anti-topo I antibody titers than healthy donors or patients with SLE. 5, 15 We explored if the fluorescence signals on multiple-bead assay and ELISA titers were associated with likelihood of SSc in the additional 24 patients and found that higher values were likely associated with SSc. However, only 3 of 4 patients with high titers had a diagnosis of SSc, and the remaining patient had a diagnosis of UCTD.
Our study has several strengths. First, we followed a stepwise approach that was instituted prospectively with RDL. Second, we reviewed all charts individually and were able to determine whether the patients had CTD due to SSc or other CTDs. Lastly, our stepwise approach is cost-effective as it sends only specimens that are positive by multiple-bead assay to RDL Reference Laboratory for further testing. In the current study, 1.4% of the samples were sent to the RDL Reference Laboratory for confirmation.
Our study also has limitations. The study included only patients who were positive by multiple-bead testing, and tests negative by ELISA were not comprehensively evaluated further by ID. We explored this in 8 subjects and found that ELISA and ID have high agreement but needs to be verified in a large sample .Therefore, we were unable to calculate true sensitivity and specificity for each test, although these have been evaluated elsewhere. 10, 13, 24, 25 Second, we did not assess if there is a cutoff point on the fluorescence signal for the multiple-bead assay on every patient but explored an additional 24 subjects who had recent laboratory work. In addition, all samples were sent to only a single laboratory (RDL); laboratories differ in their testing for autoantibodies, and this needs to be confirmed in other commercial and/or research laboratories.
In summary, we demonstrate that multiple-bead assays have a high rate of false-positive tests for the anti-topo I antibody in patients without any clinical evidence of SSc. A stepwise approach of confirmation, using both ELISA and ID, greatly improves the predictive value of antibody testing for the diagnosis of SSc and helps exclude other scleroderma variants and/or other CTDs. 
